Drug Harm Reduction

What is Drug Harm Reduction (DHR)?

Drug harm reduction (DHR) is a set of policies, programmes, services and actions related to drugs, which aim to reduce the harm to individuals, communities and society.

A core principle of harm reduction is the development of pragmatic responses to dealing with drug use. Its main emphasis is to reduce the health-related harms of continued drug use.
DHR generally includes needle and syringe programmes, supervised injection facilities and naloxone, which is used to prevent overdose deaths.

“Harm reduction refers to policies, programmes and practices that aim to minimise negative health, social and legal impacts associated with drug use, drug policies and drug laws.”

– Harm Reduction International

Benefits

Reduces the spread of HIV, Hepatitis C and other blood-borne viruses through needle and syringe programmes.
Reduces dependency through opioid substitution programmes.
Reduces social and economic impact of drug use on individuals and communities.
Reduces stigmas, prison populations and the need for law enforcement resources through decriminalisation.

Life saving potential

65

overdose death reduction

Naloxone can be used to treat opioid drug overdoses, with a survival rate of 83-100%. A case study of Dayton, Ohio, showed a 65% reduction in overdose deaths between 2017 and 2018 following the introduction of naloxone, (UNAIDS).

43

reduction in Hepatitis C cases

In Australia, 10 years of needle-syringe programmes have reduced HIV cases by up to 70% and Hepatitis C cases by up to 43%, (UNAIDS).

Research shows that syringe exchange programmes have been very effective in reducing HIV transmission, (Harm Reduction Journal).

DHR policies in practice

In Africa and around the world, countries are successfully embracing DHR policies to reduce the dangers associated with drug use.

In South Africa, opioid substitution therapy services are available in Cape Town, Pretoria and Johannesburg, servicing around 10,000 people in total, (INHSU).

In Kenya, needle and syringe programmes were introduced in 2012, and since then, over 21,000 injecting drug users have accessed the programmes. Over 9,500 people have also accessed opioid agonist therapy programmes across eight healthcare facilities, (HRI).